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San-Huang-Xie-Xin-Tang (SHXT) is a traditional Chinese medication consisting of three herbs, namely Coptidis rhizome,
Scutellariae radix and Rhei rhizome. This study aimed to examine the cardioprotective eﬀects of SHXT in a rat model of acute
myocardial apoptosis induced by ischemia/reperfusion (I/R). Vehicle (intravenous saline) or SHXT (intravenous or oral) was
administered prior to I/R (occlusion of left coronary artery for 45min followed by reperfusion for 2h). In the vehicle group,
myocardial I/R caused myocardial infarction with increased plasma cardiac enzymes, severe arrhythmia and mortality. Myocardial
apoptosis was induced by I/R as evidenced by DNA ladder and Bcl-2/Bax ratio. In the SHXT group, we found that SHXT
signiﬁcantly reduced plasma levels of cardiac enzymes, arrhythmia scores (from 5 ± 1t o2± 1, P<. 01) and mortality rate
(from 53 to 0%, P<. 01). In addition, pretreatment with intravenous SHXT reduced the infarct size dose-dependently when
compared with the vehicle group (10mgkg−1: 14.0 ± 0.2 versus 44.5 ± 5.0%, and 30mgkg−1:6 . 2± 1.2% versus 44.5 ± 5.0%,
both P<. 01). Similarly, oral administration of SHXT reduced the infarct size dose-dependently. Furthermore, SHXT markedly
decreased the apoptosis induced by I/R with increased Bcl-2/Bax ratio. Finally, we found that SHXT counteracted the I/R-induced
downstream signaling, resulting in increased myocardial eNOS expression and plasma nitrite, and decreased activation of ERK1/2,
p38 and JNK. These data suggest that SHXT has cardioprotective eﬀects against I/R-induced apoptosis, and that these eﬀects are
mediated, at least in part, by eNOS and MAPK pathways.
1.Introduction
Myocardial injury from ischemia/reperfusion (I/R) is a
clinical problem requiring invasive interventions such as
thrombolysis, angioplasty and coronary bypass surgery, to
reestablish coronary blood ﬂow and minimize cardiac dam-
age due to severe myocardial ischemia [1]. Reperfusion of an
occludedcoronaryarteryisknowntoreduceinfarctsize,pre-
serve left ventricular function, and reduce overall mortality.
However, it is now recognized that the readmission of oxy-
genated blood into previously ischemic myocardium can ini-
tiate a cascade of events that will paradoxically produce addi-
tional myocardial cell dysfunction and cell apoptosis [1–3].
San-Huang-Xie-Xin-Tang (SHXT), a widely used tradi-
tional Chinese medication, consists of three herbs, namely
Coptidis rhizome (Coptis chinesis Franch), Scutellariae radix
(Scutellaria baicalensis Georgi) and Rhei rhizome (Rheum
oﬃcinale Baill). Previous laboratory and clinical studies have
suggested that SHXT may have a role in the treatment
of various diseases including gastrointestinal disorders [4],
acute lung injury [5], septic shock [6], hypertension [7, 8]
and neuronal injury [9]. There are three major bioactive
constituents in SHXT: berberine, baicalin and baicalein [10,
11]. Berberine, one of the main components in Coptidis rhi-
zoma, has been shown to improve cardiac performance and
decrease ventricular premature complexes and mortality in2 Evidence-Based Complementary and Alternative Medicine
patients with congestive heart failure [12, 13]. In addition, it
was recently found that berberine can reduce I/R injury and
attenuate I/R-induced apoptosis in myocytes [14]. Baicalin
and baicalein are both ﬂavonoids derived from the root of
Scutellaria baicalensis, and have been reported to protect
rat cardiomyocytes against hypoxia/reoxygenation and I/R,
partly due to their scavenging capacity for reactive oxygen
species (ROS) generated during these insults [15, 16]. Fur-
thermore, Rhei rhizoma extracts reportedly possess antiox-
idant and anti-lipid peroxidation activities through their
direct suppression of mitochondrial ROS generation [17].
Even though the individual eﬀects of these three major
bioactive constituents of SHXT have been found to be bene-
ﬁcialin the settings of congestive heart failureor I/R-induced
myocardial damage [12–16], no studies have examined
whether the whole compound of SHXT also conveys cardio-
protective eﬀects. Thus, the present study aimed to inves-
tigate whether pretreatment with SHXT protects rat hearts
against I/R-induced myocardial apoptosis, and if so, whether
the anti-apoptotic eﬀects are mediated by nitric oxide (NO)
and mitogen-activation protein kinase (MAPK) pathways.
2. Methods
2.1. Materials and Reagents. The voucher specimens and
methods of extraction and analysis of SHXT were the same
as we have previously described [5]. Reagents used in this
study included: antibodies of eNOS and β-actin from Sigma-
Aldrich Inc. (St. Louis, MO, USA); antibodies of Bcl-2, Bax,
ERK1/2, phosphorylated ERK1/2, phosphorylated p38, JNK
and phosphorylated JNK from Upstate Biotechnology (Lake
Placid, NY, USA); antibody of p38 from Santa Cruz Biotech
(Santa Cruz, CA, USA); PVDF membrane and an enhanced
chemiluminescence (ECL) kit from PerkinElmer Life and
Analytical Sciences (Waltham, MA, USA), and peroxidase-
conjugated immunoglobulins from Calbiochem (Temecula,
CA, USA).
2.2. Experimental Animals. Wistar rats from the National
Laboratory Animal Breeding and Research Center (Taipei,
Taiwan) were housed under conditions of constant tempera-
ture and controlled illumination (light on between 7:30 and
19:30 hours). Food and water were available ad libitum. The
study was approved by the Animal Care and Use Committee
of the Kaohsiung Medical University.
2.3. Experimental Protocol. The I/R protocol was performed
as we have previously described [18]. In brief, male Wistar
rats weighing 250–300g were anesthetized with intraperi-
toneal pentobarbital sodium (40mgkg−1). Tracheotomy was
performed and an intubating cannula was connected to a
rodent ventilator. The animals were ventilated artiﬁcially
with room air. The left femoral artery and vein were
cannulated for the measurement of arterial blood pressure
(ABP)andheartrate(HR)viaaStathampressuretransducer
and a Biotechnometer (AD Instruments, Mountain View,
CA, USA), and for the administration of drugs, respectively.
After a left-side thoracotomy was performed at the fourth
intercostal space, the pericardium was incised and the heart
was exteriorized. A ligature (6/0 silk suture) was placed
around the left main coronary artery close to its origin.
The thread was then made into a knot as an occluder and
another thread was tied to the ﬁrst knot as a releaser. The
ends of both threads were brought outside the thoracic
cavity. Thus, the occlusion could be tightened or loosened
by pulling the thread of the releaser. The coronary artery
wasoccludedfor45min,followedby120minofreperfusion.
Sham-operated animals (sham group) underwent all of the
above-described surgical procedures except that the 6/0 silk
was passed around the left coronary artery, but was not tied.
SHXT was prepared according to the method we have
described previously [5]. Animals were randomized into
the following groups: (i) sham, (ii) operated + vehicle (i.v.
saline), (iii) operated + SHXT (10mgkg−1,i . v .b o l u s ;1 5m i n
prior to ischemia), (iv) SHXT (30mgkg−1, i.v. bolus), (v)
SHXT (10mgkg−1, oral; 1h prior to ischemia), (vi) SHXT
(30mgkg−1, oral).
2.4. Evaluation of Arrhythmia and Mortality. For all the
groups, heart rate was measured from the recordings of an
electrocardiogram (lead II) and the incidence of arrhythmia
registered in accordance with the Lambeth Conventions [19]
as ventricular tachycardia (VT), ventricular ﬁbrillation (VF)
and ventricular ectopic beat (VEB). VEB is deﬁned as a
discrete and identiﬁable premature QRS complex. VT was
diagnosed as four or more consecutive VEBs. VF was diag-
nosed when the ECG recording showed chaotic activity with
an amplitude less than that of the normal ECG. Complex
forms (e.g. bigeminy) were included in the count of VEB and
not analyzed separately. VF may be sustained or may revert
spontaneously to a normal sinus rhythm in rats. Irreversible
VF was deﬁned as VF which did not reverse within 5min
of onset. The onset and duration of arrhythmia were also
measured. The arrhythmia score for these experiments was
calculated using a previously published scale [20]. The
mortality rate was also recorded in each group.
2.5. Determination of Myocardial Infarct Size. At the end of
the experiment the coronary artery was occluded and 0.5mL
of 5% Evans blue was injected intravenously to visualize the
area at risk of infarction (AAR). The heart was then excised
and the atria were removed. The entire ventricular area was
sectioned into 2- to 3-mm thick slices from the apex to
the base and incubated in 1% triphenyltetrazolium chloride
(TTC)for15minat37◦C. TTC stained the viable tissue dark
red while the infarcted tissue remained grayish-white. The
AAR and area of infarct were both traced by hand on an
imaging system. The traced areas were then quantiﬁed by
computerized planimetry [18].
2.6. Measurement of Plasma LDH, CK-MB and Troponin I.
Myocardial cellular damage and necrosis were evaluated by
measuring plasma levels of three cardiac enzymes: lactate
dehydrogenase (LDH), troponin I and creatine kinase (CK)-
MB. The blood samples were drawn from the femoral artery
at the end of reperfusion and collected in heparinized tubes.Evidence-Based Complementary and Alternative Medicine 3
Table 1: Eﬀect of SHXT on the severity of arrhythmias induced by ischemia/reperfusion in anesthetized rats.
Groups (n = 8) Total VEBs Duration of
VT (s)
Duration of
VF (s) VT (%) VF (%) Irreversible
VF (%)
Mortality
(%)
Scores
Sham 63 ± 6 00 0 0 0 0 1 ± 1
I/R + vehicle 781 ± 49∗∗ 67 ± 3∗∗ 23 ± 3∗∗ 100 83 17 53 5 ± 1∗∗
I/R + SHXT (10mg/kg, i.v.) 326 ± 54‡ 37 ± 8+ 10 ± 3+ 100 33 0 0 3 ± 1‡
I/R + SHXT (30mg/kg, i.v.) 166 ± 28‡ 19 ± 3‡ 3 ± 1‡ 67 33 0 0 2 ± 1‡
I/R + SHXT (10mg/kg, oral) 535 ± 35+ 42 ± 4+ 20 ± 5 100 83 0 33 4 ± 1
I/R + SHXT (30mg/kg, oral) 210 ± 30‡ 21 ± 3‡ 6 ± 1‡ 67 33 0 0 2 ± 1‡
Values are mean ± SEM. Evaluation of arrhythmias described in Methods section. VEB: ventricular ectopic beats; VT: ventricular tachycardia; VF: ventricular
ﬁbrillation; I/R: ischemia/reperfusion; SHXT: San-Huang-Xie-Xin-Tang. ANOVA followed by Dunnett’s test.
∗∗P<. 01 versus sham group; +P<. 05, ‡P<. 01 versus vehicle-treated rats.
Samples were promptly centrifuged at 2000g for 15min
until measurements. Plasma levels of LDH and CK-MB
were measured with a commercial kit from Sigma-Aldrich
Inc. Serum troponin I was measured with a commercial
third-generation electrochemiluminescence immunoassay
kit (Roche Diagnostics, Indianapolis, IN, USA).
2.7. Determination of Plasma Nitrite Production. Blood sam-
ples were collected at the end of the experiment. Samples
were promptly centrifuged at 2000g for 20min at 4◦C.
Plasma supernatant was stored at −80◦C until analyzed.
NO production was spectrophotometrically determined by
assaying the plasma supernatant for nitrite using the Griess
reagent (1% sulfanilamide and 0.1% naphthylethylenedi-
amide in 5% phosphoric acid). Absorbance was measured
at 540nm and nitrite concentration was determined using
sodium nitrite as a standard.
2.8. Detection of DNA Fragmentation. Myocardial apoptosis
was qualitatively analyzed by detection of DNA fragmenta-
tion. Genomic DNA from fresh-frozen tissue was isolated
using a Purgene DNA Isolation Kit (Purgene, Minneapolis,
MN, USA) according to the manufacturer’s instructions.
Twenty-ﬁve micrograms of DNA was loaded onto 2%
agarose gel containing 0.5μgmL −1 ethidium bromide. DNA
electrophoresis wascarried out at 50 V for1-2h. DNA ladder
formation, a hallmark of tissue apoptosis, was visualized
under ultraviolet light and photographed for a permanent
record.
2.9. Western Blotting. Left ventricles were removed at the
end of the experiment, and lysed with lysis buﬀer [20mM
Tris-HCl(pH7.5),1mMdithiothreitol(DTT),5mMEGTA,
2mM EDTA, 0.5mM PMSF, 20μMl e u p e p t i na n d2 0 μM
aprotinin]. After sonication, the lysates were centrifuged and
the proteins were separated by electrophoresis on SDS-PAGE
(10–14%) and transferred onto a polyvinylidene diﬂuoride
(PVDF)-plus membrane. After blocking for 1h in 5% non-
fat dry milk in Tris-buﬀered saline, the membrane was
incubated with the desired primary antibody for 2h. The
membrane was then treated with appropriate horseradish
peroxidase conjugated secondary antibody (diluted 1:1000),
and the immunoreactive bands were detected with enhanced
chemiluminescence reagents (PerkinElmer Life and Analyti-
cal Sciences).
2.10. Statistical Analysis. The results are expressed as mean
± SEM. Statistical diﬀerences were estimated by one-way
analysis of variance (ANOVA) followed by Dunnett’s test. A
value of P<. 05 was considered signiﬁcant.
3. Results
3.1. Ventricular Arrhythmia and Mortality Rate. SHXT pro-
duced markedly antiarrhythmic eﬀects in anesthetized rats
as shown in Table 1. I/R caused pronounced arrhythmo-
genic activity with 100% VT and 63% VF. In both oral
(10mgkg−1) and i.v. bolus SHXT (10mgkg−1)t r e a t e d
groups, there were signiﬁcant decreases in the number of
VEBs (from 781 ± 49 to 535 ± 35 and 326 ± 54, resp.,
P<. 05) and the incidence of VF (both from 63 to 25%)
and irreversible VF (both from 13 to 0%). Similarly, both
oral (30mgkg−1) and i.v. bolus administration of SHXT
(30mgkg−1) signiﬁcantly reduced the total number of VEBs
(from 781 ± 49 to 210 ± 30 and 166 ± 28, resp., P<. 01)
and the incidence of VT (both from 100 to 75%), VF (both
from 63 to 25%) and irreversible VF (both from 13 to 0%).
Moreover, the duration of VT and VF was also signiﬁcantly
reduced in all SHXT-treated groups except for the group
with low dose oral administration (10mgkg−1). The most
marked reductions in the arrhythmia scores were observed
in high dose (30mgkg−1) groups with oral and i.v. bolus
administration (both from 5 ± 1t o2± 1, P<. 01). More
importantly, SHXT decreased the mortality rate from 53 to
0% (P<. 01).
3.2. Myocardial Infarct Size. SHXT has protective eﬀects
against myocardial infarction, as shown in Figure 1(a).Th e r e
were no signiﬁcant diﬀerences in the size of AAR among all
groups. The vehicle group had a high proportion of infarcted
tissue (INF/AAR ratio) of 44.5 ± 5.0%, which was signif-
icantly reduced by pretreatment with SHXT. Intravenous
administration of SHXT at doses of 10 and 30mgkg−1
resulted in INF/AAR ratios of 14.0 ± 0.2% (P<. 01) and
6.2 ± 1.2% (P<. 01), respectively. Oral administration of4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of SHXT on myocardial infarct size and plasma levels of CK-MB, LDH and troponin I in rat hearts subjected to I/R. (a) Bar
graphs show area at risk of infarction indexed to total left ventricle (AAR/Total LV), infarcted area indexed to area at risk of (INF/AAR), and
infarcted area indexed to total left ventricle (INF/Total LV). (b)–(d) Eﬀects of pretreatment with SHXT on plasma levels of cardiac enzymes.
Each value represents the mean ± SEM of six rats. ∗∗P<. 01 versus sham group; +P<. 05, ‡P<. 01 versus vehicle-treated rats. ANOVA
followed by Dunnett’s test.
SHXT also dose-dependently reduced this ratio. Similarly,
theINF/totalLVratiowasalsosigniﬁcantlylowerinratswith
SHXT-treatment than in vehicle-treated rats.
3.3. Plasma CK-MB, LDH and Troponin I. As shown in
Figures 1(b)–1(d), in the sham group, all three cardiac
enzymes remained at low levels at the end of surgery,
indicating that a sham-operation without I/R did not result
in signiﬁcant myocardial injury. In the vehicle group, I/R
causedincreasedlevelsofallthesecardiacenzymes.However,
pretreatment with SHXT by intravenous injection and oral
administration both attenuated the increases of all these
cardiac enzymes, in a concentration-dependent manner.
3.4. Myocardial DNA Fragmentation. In the sham group,
there was no DNA fragmentation detected in myocardial
tissue (Figure 2(a), lane 1). In contrast, the formation of
DNA nucleosome fragmentation was clearly detected in
myocardial tissues in the vehicle group (Figure 2(a),l a n e
2). Both intravenous and oral administration of high dose
(30mgkg−1) SHXT markedly decreased myocardial DNA
fragmentation (Figure 2(a),l a n e s4a n d6 ) .
3.5. Myocardial Expression of Bcl-2 and Bax. As shown in
Figure 2(b), I/R caused decreased expression of Bcl-2 protein
and increased expression of Bax protein in myocardium,
resulting in a decrease of the Bcl-2/Bax ratio, indicating
I/R-inducedapoptosis.However,intravenousadministration
of SHXT prevented the decrease of the Bcl-2/Bax ratio
dose-dependently. Similarly, but to a lesser extent, oral
administration of SHXT at a high dose attenuated the
decrease of the Bcl-2/Bax ratio.Evidence-Based Complementary and Alternative Medicine 5
M 1 2 345 6
1000 bp
500 bp
(a)
0
20
40
60
80
100
120
140
β-actin
Bax
Bcl-2
B
c
l
-
2
/
B
a
x
r
a
t
i
o
(
%
o
f
s
h
a
m
g
r
o
u
p
)
Sham Vehicle
+I/R
10 30 10 30
SHXT iv + IR SHXT oral + I/R
Sham
Vehicle
+
I / R 1 03 01 03 0
SHXT iv + IR SHXT oral + I/R
∗∗
‡
‡
‡
(b)
Figure 2: SHXT attenuated ischemia/reperfusion (I/R)-induced
myocardial apoptosis by the DNA ladder and Bcl-2/Bax ratio. (a)
DNA fragmentation was detected by agarose gel electrophoresis. M
represents marker; lane 1 represents sham tissue; lane 2 represents
vehicle-treated tissue; lane 3 represents SHXT 10mg/kg-treated
tissue (i.v.); lane 4 represents SHXT 30 mg/kg-treated tissue (i.v.);
lane 5 represents SHXT 10mg/kg-treated tissue (oral); lane 6
representsSHXT30mg/kg-treatedtissue(oral).Similarresultswere
obtainedinfourotherexperiments.(b)Quantitativeanalysisonthe
Bcl-2/Bax ratio by western blots. Each value represents the mean
± SEM of six rats. ∗∗P<. 01 versus sham group; +P<. 05,
‡P<. 01 versus vehicle-treated rats. ANOVA followed by Dunnett’s
test.
3.6. Myocardial eNOS Protein and Plasma NO Production.
As shown in Figure 3(a), I/R decreased the expression of
myocardial eNOS protein. However, both intravenous injec-
tionandoraladministrationofSHXTpreventedthedecrease
dose-dependently. Similarly, as shown in Figure 3(b),I / R
caused a decreased level of plasma nitrite, and SHXT had a
signiﬁcantly antagonizing eﬀect on this change, in a dose-
dependent manner.
3.7. MAPK Pathway. We ﬁnally explored the signaling path-
way of SHXT-mediated anti-apoptotic eﬀects, and examined
the MAPK cascades, the upstream signaling molecules in
apoptotic reactions. As shown in Figure 4(a), in comparison
with the sham group, the phosphorylation of ERK1/2 was
increased in the vehicle group due to I/R. However, the I/R-
induced activation of ERK1/2 was signiﬁcantly abolished by
pretreatment with SHXT. In addition, SHXT also attenuated
the activation of p38 induced by I/R (Figure 4(b)), even
though this eﬀect was not signiﬁcant when a low dose
(10mg kg−1) was administered orally. Similarly, I/R-induced
activation of JNK was attenuated by SHXT (Figure 4(c)).
4. Discussion
ThisistheﬁrststudytodemonstratethatSHXT,atraditional
Chinese medicinal formula, has composite cardioprotective
eﬀects against I/R of antiarrhythmia, reducing infarct size
and increased survival in rats. In addition, SHXT possesses
a potent inhibitory eﬀect against I/R-induced myocardial
apoptosis, which may be mediated, at least in part, by eNOS
and MAPK pathways.
In our rat model with myocardial damage induced by
I/R,weﬁrstfoundthatpretreatmentwithSHXTsigniﬁcantly
decreased the rhythm disturbances, mortality rate and
myocardial infarct size. During an ischemic insult, myocytes
may release a variety of intracellular enzymes and proteins
into the blood. In the present study, we examined multiple
biochemical markers including CK-MB, LDH and troponin
I to detect cardiac cellular damage caused by I/R. We found
that I/R-induced elevations of plasma LDH, CK-MB and
troponin I were markedly blunted when rats were pretreated
with SHXT.
Two distinct types of myocardium cell death, necrosis
and apoptosis, have been linked with I/R-induced myocar-
dial injury. Internucleosomal DNA fragmentation observed
in agarose gels [21], chromatin condensation observed
by Hoechst 33342 staining and ﬂow cytometric analysis
for translocation of phospholipid phosphatidylserine by
annexin V/PI staining [22], have been widely used to deﬁne
myocardial apoptosis. The mitochondria apoptotic pathway
has been described as important for apoptotic cell death
signaling for mammalian cells [23]. Apoptosis after I/R has
been found to be associated with increased levels of Bax
protein and also with a decreased Bcl-2/Bax ratio [24]. The
overexpression of Bcl-2 in mice can signiﬁcantly inhibit
apoptosis and decrease infarct size in the heart after I/R [25].
Therefore, we investigated the role of Bcl-2 family proteins
in the anti-apoptotic eﬀects of SHXT. Our results showed6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: SHXT up-regulated eNOS protein expression and then
promoted plasma NO production after I/R. (a) The expression
level of eNOS protein in infarcted myocardial tissues was measured
by immunoblot assay. The relative ratio of protein/β-actin protein
was quantiﬁed by densitometric analyses. (b) NO production
was detected spectrophotometrically by measuring its metabolite,
nitrite. Each value represents the mean ± SEM of six rats. ∗P<. 05
versus sham group; +P<. 05, ‡P<. 01 versus vehicle-treated rats.
ANOVA followed by Dunnett’s test.
thatSHXT treatmentsigniﬁcantly increasedBcl-2expression
and decreased Bax, suggesting that changes in the ratio of
proapoptotic and antiapoptotic Bcl-2 family proteins may
contribute to the antiapoptotic and cardioprotective eﬀects
of SHXT on I/R injury (Figure 5).
Numerous studies have demonstrated the cardiopro-
tective eﬀects of NO during I/R. In addition, it has
been demonstrated that the eﬀects of NO on myocardial
I/R injury include both pro- and anti-apoptotic eﬀects
depending on the source of NO [26, 27]. However, precise
mechanisms underlying these eﬀects are complex and not
completely understood. For example, in eNOS−/− mice,
myocardial injury was found to be exacerbated following
I/R, suggesting the protective role of eNOS-derived NO
[28, 29]. Additionally, treatment with statins has been found
to reduce I/R injury after myocardial infarction, via PI3-
kinase/AktandeNOS-mediatedpathwayswithincreasedNO
availability [30]. Some studies suggest that the beneﬁcial
eﬀects of NO from eNOS are mediated by regulation of
vascular tone, superoxide radical scavenging and inhibition
of neutrophil adherence and inﬁltration [27–31]. Our results
were consistent with previous studies showing that the
myocardial expression of the eNOS protein was markedly
decreased after I/R injury. In addition, we showed that
administration of SHXT increased the expression of the
eNOS protein, promoted NO generation and attenuated
myocardial apoptosis in the I/R animal model. Collectively,
thepresentstudysuggeststhatSXHTmayprotectmyocardial
tissue from apoptosis by modulating eNOS expression
(Figure 5).Ourresultsareinlinewitharecentstudyshowing
that hydroxysaﬄor yellow A, a ﬂavonoid of Carthamus
tinctorius extracts, can inhibit I/R-induced opening of mito-
chondrial permeability transition pores through enhanced
NO production by eNOS activation [31].
Emerging evidence suggests that MAPK-signaling cas-
cades play an important role in oxidative stress-induced
apoptotic cell death [31, 32]. The MAPK family has been
classiﬁed into three major subfamilies: the extracellular
signal-regulated kinase (ERK), the c-Jun N-terminal kinase
(JNK) and the p38 MAPK. They are activated in response
to myocardial I/R, and it is generally believed that the
activations of ERK1/2 (beneﬁcial) and p38 MAPKs-JNKs
(deleterious)exertoppositeeﬀectsonpost-ischemicmyocar-
dial apoptosis and cardiac function recovery [33, 34].
Namely, activation of ERK contributes to cell diﬀerentiation,
proliferationandsurvival,whereasJNKandp38areactivated
by pro-inﬂammatory cytokines and environmental stresses
andpromoteapoptosis[33].However,thereissomeevidence
suggestingthatERK1/2alsocontributestocelldeathinmany
organ systems. For example, ERK1/2 was activated in an
animal model of I/R-induced brain injury, and inactivation
of ERK1/2 reduced the extent of tissue damage [35, 36]. In
cardiomyocytes, a recent study has also shown activation
of ERK1/2 to be important in Bcl-2 family-mediated cell
apoptosis caused by doxorubicin [37]. Therefore, we ﬁnally
examined the potential eﬀects of SHXT on the activation
of the diﬀerent MAPK cascades induced by I/R. We found
that activations of ERK1/2, p38 and JNK were observed in
rat hearts subjected to I/R, and pretreatment with SHXT
signiﬁcantly decreased the activation of these activations.
Our results indicate that SHXT suppresses activations of
all three subfamilies of MAPK-signaling cascades induced
by myocardial I/R injury. Even though these data suggest
that SHXT may inhibit the survival action of ERK1/2, we
speculate that this eﬀect may be oﬀset by p38 and JNK, with
the net eﬀect of MAPKs potentially contributing to the anti-
apoptotic action of SHXT.Evidence-Based Complementary and Alternative Medicine 7
0
20
40
60
80
100
120
140
160
ERK1/2
p-ERK1/2
O
p
t
i
c
a
l
d
e
n
s
i
t
y
u
n
i
t
s
o
f
p
h
o
s
p
h
o
r
y
l
a
t
e
d
E
R
K
1
/
2
(
%
o
f
s
h
a
m
g
r
o
u
p
)
Sham Vehicle
+I/R
10 30 10 30
SHXT iv + IR SHXT oral + I/R
Sham
Vehicle
+
I / R 1 03 01 03 0
SHXT iv + IR SHXT oral + I/R
∗∗
+
‡
+
+
(a)
0
20
40
60
80
100
120
140
160
180
200
p-p38
p38
O
p
t
i
c
a
l
d
e
n
s
i
t
y
u
n
i
t
s
o
f
p
h
o
s
p
h
o
r
y
l
a
t
e
d
p
3
8
(
%
o
f
s
h
a
m
g
r
o
u
p
)
Sham Vehicle
+I/R
10 30 10 30
SHXT iv + IR SHXT oral + I/R
Sham
Vehicle
+
I / R 1 03 01 03 0
SHXT iv + IR SHXT oral + I/R
∗∗
+
‡
+
(b)
0
20
40
60
80
100
120
140
160
p-JNK
JNK
O
p
t
i
c
a
l
d
e
n
s
i
t
y
u
n
i
t
s
o
f
p
h
o
s
p
h
o
r
y
l
a
t
e
d
J
N
K
(
%
o
f
s
h
a
m
g
r
o
u
p
)
Sham Vehicle
+I/R
10 30 10 30
SHXT iv + IR SHXT oral + I/R
Sham
Vehicle
+
I / R 1 03 01 03 0
SHXT iv + IR SHXT oral + I/R
∗∗
+
++
(c)
Figure 4: Eﬀects of SHXT on activations of ERK1/2 (a), p38 (b) and JNK (c) induced by I/R. Each value represents the mean ± SEM of six
rats. ∗∗P<. 01 versus sham group; +P<. 05, ‡P<. 01 versus vehicle-treated rats. ANOVA followed by Dunnett’s test.8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Proposed mechanisms of the cardioprotective eﬀects
of SHXT on ischemia/reperfusion-induced myocardial apoptosis
according to results in the present study. SHXT can signiﬁcantly
inhibit myocardial apoptosis induced by ischemia/reperfusion, at
least in part, by activating eNOS expression and blunting MAPK-
mediated cascades.
In conclusion, these results demonstrate for the ﬁrst
time that SHXT, a Chinese herbal medicine, has potent
cardioprotective eﬀects with anti-apoptosis in rats with
myocardialI/Rinjury,andthattheseantiapoptoticeﬀectsare
mediated partly by eNOS and MAPK pathways (Figure 5).
This study implicates that SHXT is a potentially useful drug
that can be applied clinically in the prevention or treatment
of myocardial injury caused by I/R.
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